Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
November 01 2023 - 9:00AM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced that Panome
Bio has joined its COE Program. Panome Bio is a metabolomics and
proteomics services company that provides biopharma innovators
unparalleled access to the biomolecules closest to phenotype using
its proprietary Next Generation Metabolomics™ technology. Panome
Bio joins Seer’s global COE network of leading service providers,
who are all committed to accelerating the adoption of unbiased,
deep proteomics at scale. Seer COEs have been selected for their
demonstrated expertise in proteomics, their ability to deliver the
highest quality service, and their commitment to partnering to
expand the ecosystem around deep, unbiased proteomics using Seer’s
technology. Seer’s COE network makes it easier for customers around
the world to access the value of the Proteograph Product Suite and
the new Proteograph XT Assay.
“At Seer, we are passionate about empowering more researchers to
access deep, unbiased proteomics so that we can really begin to
fundamentally understand biology in a functional and dynamic way,”
said Omid Farokhzad, CEO and Founder of Seer. “We have been
impressed with Panome Bio’s approach to serving biopharma, from
their focus on understanding the customer’s goals, to their
approach to data analysis, to reports that go beyond a list of data
points. We see them as an ideal partner in making it easier for the
scientific community to accelerate its insights into biology and
disease with peptide-level proteomic data, complemented by
metabolomic data. We are thrilled to be partnering with a leading
multi-omics provider like Panome Bio to help realize this
potential.”
Panome Bio’s Next-Generation Metabolomics technology was
developed by Chief Scientific Officer, Dr. Gary Patti, whose lab is
known for its many key advancements in the field of metabolomics.
“Some of the most exciting and insightful experiments to
interrogate biology are currently not being done by many
researchers who would greatly benefit from them. This is not only
due to technological access, but also challenges of data
interpretation.” said Dr. Patti. “By combining deep proteomic
insights at the peptide level with our proprietary metabolomics
workflow, Panome Bio will enable first-of-their-kind studies with
robust pathway analyses to significantly advance research in
biomarker discovery and drug development.”
The Proteograph XT Assay in combination with Seer’s Proteograph
Product Suite, enables deep, unbiased proteomics studies with
unprecedented sight, scope, speed, and scale. Seer’s proprietary
engineered nanoparticles enhance the detection of novel variants
and biomarkers, enabling researchers to gain direct sightlines into
the proteome at the peptide level, with a depth of greater than
6,000 proteins and more than 55,000 peptide IDs in complex samples
such as plasma. The Proteograph XT solution is species and sample
agnostic, adding flexibility and scope to any study, supporting
samples from biofluids to skeletal muscle, and studies leveraging
from small to large model organisms. With a fully automated
workflow and minimal hands-on time, researchers can now conduct
unbiased proteomics studies of significance with hundreds or
thousands of samples, quickly and efficiently.
More information on the Seer COE Program can be found at
https://seer.bio/company/service-providers-of-seer-technology/.
About SeerSeer is a life sciences company
developing transformative products that open a new gateway to the
proteome. Seer’s Proteograph™ Product Suite with the new
Proteograph XT Assay is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
About Panome BioPanome Bio is a discovery
services contract research organization that helps its clients
profile the metabolome and proteome to further their research in
disease and drug development. Panome Bio provides a comprehensive
workflow including experimental design, sample preparation and
analysis, and data processing. For more information, please visit
www.panomebio.com.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Seer’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Seer’s actual results, performance, or achievements to be
materially different from those expressed or implied by the
forward-looking statements. These statements include but are not
limited to statements regarding the delivery of unprecedented depth
and scale in complex biological samples, the integration of data
and analysis protocols, understanding health and disease,
acceleration of insights into biology, the detection of novel
variants and biomarkers, the depth of protein and peptide
identification, and the Seer Centers of Excellence Program. These
and other risks are described more fully in Seer’s filings with the
Securities and Exchange Commission (“SEC”) and other documents that
Seer subsequently files with the SEC from time to time. Except to
the extent required by law, Seer undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Media Inquiries:Karen Possematopr@seer.bio
Alexandra Harrison, PhDalexandra.harrison@panomebio.com
Investor Inquiries: Carrie
Mendivil investor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Oct 2023 to Oct 2024